In this video, Paul Richardson, MD, director of clinical research at Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discusses the phase III DETERMINATION study in multiple myeloma presented at ASCO Annual Meeting.
Richardson finds that as the study continues to build, the future of treatment is strong as the platform for new novel therapies continues to grow.
“In the absence of a survival benefit, patients have choices,” Richardson said. “They can indeed keep transplant in reserve in selected patients if that’s deemed appropriate.”
